[1] Ogba N, Arwood NM, Bartlett NL, et al.Chimeric antigen receptor T-cell therapy[J].J Natl Compr Canc Netw, 2018, 16(9):1092-1106. [2] Pehlivan KC, Duncan BB, Lee DW.CAR-T cell therapy for acute lymphoblastic leukemia:transforming the treatment of relapsed and refractory disease[J].Curr Hematol Malig Rep, 2018, 13(5):396-406. [3] Wang ZG, Wu ZQ, Liu Y, et al.New development in CAR-T cell therapy[J].J Hematol Oncol, 2017, 10(1):1-11. [4] Zhao ZJ, Chen Y, Francisco NM, et al.The application of CAR-T cell therapy in hematological malignancies:advantages and challenges[J].Acta Pharm Sin B, 2018, 8(4):539-551. [5] Maude SL, Frey N, Shaw PA, et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med, 2014, 371(16):1507-1517. [6] Davila ML, Riviere I, Wang XY, et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J].Sci Transl Med, 2014, 6(224):224ra25. [7] Zhang J, Medeiros LJ, Young KH.Cancer immunothera py in diffuse large B-cell lymphoma[J].Front Oncol, 2018, 8:351.DOI:10.3389/fonc.2018.00351. [8] Watkins MP, Bartlett NL.CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas[J].Expert Opin Investig Drugs, 2018, 27(7):601-611. [9] Gauthier J, Turtle CJ.Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy[J].Curr Res Transl Med, 2018, 66(2):50-52. [10] Annesley CE, Summers C, Ceppi F, et al.The evolution and future of CAR T cells for B-cell acute lymphoblastic leukemia[J].Clin Pharmacol Ther, 2018, 103(4):591-598. [11] Wang ZG, Han WD.Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy[J].Biomark Res, 2018, 6(1):1-10. [12] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组.中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J].中华血液学杂志, 2016, 37(10):837-845. [13] Dholaria BR, Bachmeier CA, Locke F.Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities[J].BioDrugs, 2019, 33(1):45-60. [14] Neelapu SS, Tummala S, Kebriaei P, et al.Chimeric antigen receptor T-cell therapy—assessment and management of toxicities[J].Nat Rev Clin Oncol, 2018, 15(1):47. [15] Neelapu SS, Locke FL, Bartlett NL, et al.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma[J].N Engl J Med, 2017, 377(26):2531-2544. [16] Liu DL, Zhao JJ.Cytokine releasesyndrome:grading, modeling, and new therapy[J].J Hematol Oncol, 2018, 11(1):1-7. [17] Zhang LN, Song YP, Liu DL.CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia:factors affecting toxicities and long-term efficacies[J].J Hematol Oncol, 2018, 11(1):1-5. [18] Gust J, Hay KA, Hanafi LA, et al.Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells[J].Cancer Discov, 2017, 7(12):1404-1419. [19] Hu YX, Sun J, Wu Z, et al.Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy[J].J Hematol Oncol, 2016, 9(1):1-5. [20] Lee DW, Gardner R, Porter DL, et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood, 2014, 124(2):188-195. [21] Le RQ, Li L, Yuan WS, et al.FDA approval summary:tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome[J].Oncol, 2018, 23(8):943-947. [22] Park JH, Rivière I, Gonen M, et al.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J].N Engl J Med, 2018, 378(5):449-459. [23] Kotch C, Barrett D, Teachey DT.Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome[J].Expert Rev Clin Immunol, 2019, 15(8):813-822. [24] Gallenga C, Pandolfi F, Al C, et al.Interleukin-1 family cytokines and mast cells:activation and inhibition[J].J Biol Regul Homeost Agents, 2019, 33(1):1. [25] Giavridis T, van der Stegen SJC, Eyquem J, et al.CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade[J].Nat Med, 2018, 24(6):731. |